following a resubmission:
lecanemab (Leqembi®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients that are apolipoprotein E ɛ 4 (ApoEɛ4) heterozygotes or non-carriers.
In a randomised, double-blind, phase III study, lecanemab reduced the cognitive and functional decline associated with early Alzheimer’s disease compared with placebo at 18 months.
The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Medicine details
- Medicine name:
- lecanemab (Leqembi)
- SMC ID:
- SMC2811
- Indication:
For treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease in adult patients that are apolipoprotein E ɛ 4 (ApoEɛ4) heterozygotes or non-carriers.
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 07 July 2025